Scarica l'app Stockscreener
36.10
1.26%
0.45
Dopo l'orario di chiusura:
35.81
-0.29
-0.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$35.65
Aprire:
$35.65
Volume 24 ore:
2.14M
Relative Volume:
0.55
Capitalizzazione di mercato:
$15.21B
Reddito:
$2.26B
Utile/perdita netta:
$1.09B
Rapporto P/E:
15.41
EPS:
2.3431
Flusso di cassa netto:
$2.70B
1 W Prestazione:
-1.12%
1M Prestazione:
+3.56%
6M Prestazione:
+20.01%
1 anno Prestazione:
+26.80%
Intervallo 1D:
$35.55
$36.14
Intervallo di 1 settimana:
$35.24
$36.89
Portata 52W:
$24.05
$36.89
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.10 | 15.38B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma plc Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
Citigroup Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Citigroup maintains Buy rating, raises PT for Royalty Pharma to $42. - AInvest
Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth - Investing.com UK
Royalty Pharma (RPRX) PT Raised to $42 at Citi - StreetInsider
What drives Royalty Pharma plc stock priceFree Technical Analysis Support - jammulinksnews.com
What analysts say about Royalty Pharma plc stockOver 200% growth - jammulinksnews.com
C WorldWide Group Holding A S Acquires New Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Los Angeles Capital Management LLC Purchases 1,040,234 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Edgestream Partners L.P. Acquires New Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stake Raised by Victory Capital Management Inc. - MarketBeat
Is Royalty Pharma plc a good long term investmentFree Trend-Following Techniques - jammulinksnews.com
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Cullen Frost Bankers Inc. Acquires 247,903 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share - AInvest
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share - AInvest
Royalty Pharma PLC Announces Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Declares Third Quarter 2025 Dividend - The Globe and Mail
Royalty Pharma announces $0.22 per share dividend for Q3 2025 - Investing.com
Royalty Pharma plc (RPRX) Declares $0.22 Quarterly Dividend; 2.5% Yield - StreetInsider
Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share - AInvest
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Bryn Mawr Capital Management LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc stock a good hedge against inflationHigh Potential Safe Trades - Newser
Royalty Pharma adds two independent directors to board By Investing.com - Investing.com South Africa
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times
Royalty Pharma adds two independent directors to board - Investing.com
Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative
Royalty Pharma Appoints Denali CMO and Warburg Pincus Veteran to Board Following Major Acquisition - Stock Titan
Strata Wealth Advisors LLC Invests $387,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Cerity Partners LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Has $45.53 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Royalty Pharma Q2 2025 Earnings Call: Key Details for August 6 Pre-Market Release - Stock Titan
Why Royalty Pharma plc stock attracts strong analyst attentionDaily Swing Candidates - Newser
How Royalty Pharma plc stock performs during market volatilityMarket Timing Advice - beatles.ru
What makes Royalty Pharma plc stock price move sharplyFree Trading Group - Newser
M&T Bank Corp Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):